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Abstract
Objectives: While various clinical and pharmacological determinants for chemotherapy-associated cognitive impairment
have been identified, conflicting evidence suggests that cytokines might play an intermediary role. The objective of this
systematic review was to evaluate the current evidence pertaining to the associations among chemotherapy, cytokines
induction and cognitive impairment in cancer patients.
Methods: A literature search with PubMed and SciVerse Scopus was conducted in March 2013 to gather relevant articles
and abstracts that fulfilled the inclusion and exclusion criteria. This review included studies that had performed objective
and/or subjective cognitive assessments and cytokine measurements on defined populations of cancer patients who
received chemotherapy.
Results: High methodological heterogeneity existed among the selected studies which differed in cancer populations,
subject characteristics, cognitive endpoints, types of cytokines tested and their measurement methods. Weak to moderate
correlations were observed between IL-1b, IL-6, TNF-a levels, and different degrees of cognitive impairment. Different types
of chemotherapy treatments might lead to varying presentations and severities of cytokine-induced cognitive impairment.
Notably, the time concordance between the onset of cytokine induction and occurrence of cognitive impairment was not
well elucidated. A number of confounding factors was identified to interfere with the expression levels of cytokines; these
confounders included subjects’ cancer types, ages, genders, genetics and psychosocial characteristics such as anxiety,
depression and fatigue.
Conclusion: Although existing studies observed cognitive impairment and cytokine dysregulation in patients who receive
chemotherapy, our results suggest that the intermediary role of cytokines in post-chemotherapy cognitive impairment is
still controversial and requires further evaluation. A list of methodological recommendations is proposed to harmonize
future studies of this subject matter.
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Introduction
Numerous recent studies have been conducted on cognitive
changes in breast cancer patients[1–3]. These cancer survivors
commonly experience a subtle yet notable change in cognitive
function after receiving chemotherapy, a phenomenon termed
‘‘chemobrain’’ or ‘‘chemofog’’. The reported prevalence of
cognitive impairment varies widely from 6 to 75%, with patients
experiencing moderate to severe levels of impairment across
studies[3,4]. Cognitive impairment includes deficits in various
cognitive domains, such as impaired memory, alertness or
attention, learning, processing speed and executive functioning.
As cognitive changes have an adverse effect on cancer patients’
daily functioning and quality of life[2,5–7], much recent research
has attempted to ascertain the determinants and mechanisms that
contribute to this ‘‘chemobrain’’ phenomenon.
Multiple factors have been postulated as determinants of
cognitive changes in cancer patients, including demographical,
physiological, psychological, pathological and pharmacological
determinants[4,8,9]. Notably, recent experimental studies have
suggested that pro-inflammatory cytokines may be mediators of
chemotherapy-associated cognitive changes[10–17]. Cytokine
induction in the central nervous system has been suggested to
mediate "sickness behavior" in patients with severe infection or
cancer, together with the adverse neuropsychiatric effects of
treatment with interferon and interleukins[13]. It has been widely
acknowledged that cytokines and inflammatory markers may give
rise to a cluster of cancer-related symptoms including fatigue,
depression and stress, which are also associated with cognitive
changes[10–30]. In summary, cytokines play a dominant role in
the neuroimmunoendocrine processes-induced by cancer cells and
cytotoxic chemotherapy.
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Chemotherapeutic agents, which are mostly unable to cross the
blood-brain-barrier (BBB) due to its molecular size, can cause
toxicity to the brain indirectly via the pro-inflammatory cytokine
pathways. Cytokines can then penetrate the BBB readily by active
transport and through circumventricular regions in the
brain[30,31]. They bind to the endothelial receptors in the brain
vasculature to stimulate the release of other inflammatory
mediators, such as cell adhesion molecules, chemokines, nitric
oxide and prostaglandins, that impede the integrity of the
BBB[32,33]. In the brain, cytokines elicit local inflammation
through oxidative and nitrosative processes, especially in the
hippocampus and regions of the brain with abundant cytokine
receptors[34–40]. For example, animal studies have suggested that
doxorubicin could increase the level of circulating TNF-a that
penetrates the BBB to cause the induction of nitric oxide synthase
leading to overproduction of reactive nitric species and reactive
oxygen species that act on brain mitochondria to cause oxidative
stress[10]. These reactions would ultimately lead to the clinical
presentations of cognitive dysfunction[15,16,41–44]. Figure 1
provides a brief summary of how cytokines may function as a
mechanistic mediator in chemotherapy-associated cognitive
changes.
To gain a better understanding of the role that cytokines play in
the ‘‘chemobrain’’ phenomenon, it is necessary to evaluate the
sequence of events involving chemotherapy and the cytokine-
based immune response that affects cognitive functioning in cancer
patients. Thus far, there is a paucity of studies specifically
evaluating the relationship between chemotherapy, cytokine
induction and cognitive changes. This review is designed to
investigate the possible mediatory role that cytokines play in the
neurocognitive sequelae of chemotherapy, and to identify potential
confounding factors that may affect the accurate assessment of
cytokines as biological determinants of chemotherapy-induced
cognitive impairment. The review findings are used to propose a
set of methodological guidelines for studies involving this subject
matter.
Methods
A literature search was conducted using PubMed and SciVerse
Scopus in March 2013. Only articles in English published before
March 2013 were reviewed. The search was carried out using the
following combination of keywords: ‘‘cancer,’’ ‘‘chemotherapy,’’
‘‘cytokines,’’ ‘‘chemokines,’’ ‘‘cognitive,’’ ‘‘neuropsychological,’’
‘‘neurotoxicities,’’ ‘‘chemobrain,’’ ‘‘chemofog,’’ ‘‘tumor necrosis
factor or TNF,’’ ‘‘interferon or IFN,’’ ‘‘interleukin or IL,’’ ‘‘colony-
stimulating factors or CSF,’’ ‘‘growth factors,’’ ‘‘memory,’’
‘‘concentration,’’ ‘‘processing speed,’’ ‘‘learning,’’ and ‘‘alertness.’’
The Medical Subject Headings (MESH) application in PubMed
was also utilized. The review included original reports and
abstracts from oncology meetings, such as the American Society of
Clinical Oncology (ASCO), the European Society for Medical
Oncology (ESMO), the San Antonio Breast Cancer Symposium
(SABCS), the Multinational Association of Supportive Care in
Cancer (MASCC) and the International Cognition and Cancer
Figure 1. Role of cytokines and other determinants in chemotherapy-induced cognitive impairment. Multiple factors have been
postulated as determinants of cognitive changes in cancer patients, including demographical, physiological, psychological, pathological and
pharmacological determinants. Recent experimental studies have suggested that pro-inflammatory cytokines may be mediators of chemotherapy-
associated cognitive changes.
doi:10.1371/journal.pone.0081234.g001
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Task Force (ICCTF). Additional information was obtained from
virtual and poster presentations for abstracts presented at oncology
meetings.
The reviewed studies met the following inclusion criteria: (1)
clinical studies conducted on defined cancer populations; (2)
included the administration of cytotoxic chemotherapy drugs or
regimens; (3) involved the quantitative measurement of a specific
panel of cytokines, such as interleukins (IL), interferon (IFN),
tumor necrosis factor (TNF), soluble TNF receptor (sTNF-R),
growth factors and colony-stimulating factors (CSF); and (4)
included the objective and/or subjective assessment of overall
cognition or at least one cognitive domain.
Studies were excluded if they were meta-analyses, reviews,
commentaries or case studies; if they focused on peripheral
neurotoxicity or brain malignancy-related cognitive impairment;
or if cytokine and/or cognitive measurements were omitted. The
corresponding authors of the included articles were contacted
when additional information on the study was needed. Data
extraction and summary of study results were conducted by the
investigators independently, and any disparities in the findings
were reconciled.
Results and Discussion
Overview of Literature Search
The results of the literature search are depicted in Figure 2.
Thirteen selected articles fulfilled the inclusion criteria[22,41,45–
55], of which six articles were full texts and seven articles were
abstracts presented at oncology meetings. Four abstracts [45–48]
were found to involve the same colorectal cancer populations at
different times; therefore, the abstract with either the latest or the
most comprehensive set of data was utilized in the review. One
abstract[54] was identical to a full text article[53].
Heterogeneity of Studies
Despite fulfilling the inclusion and exclusion criteria, the
objectives of most of the included studies were not fully aligned
with the purpose of determining the relationship between
chemotherapy, cytokine levels and cognitive impairment. Some
studies did not investigate the association between post-chemo-
therapy cognitive changes and cytokine dysregulation. There was
a high level of heterogeneity among the selected studies. These
inconsistencies included variations in patient characteristics, types
of chemotherapy, types of cytokines measured, methods of
measuring cytokines and types of cognitive assessments. Hetero-
geneity existed because cognitive function was not the primary
endpoint in some of the selected studies. For example, two
studies[22,50] were designed primarily to investigate the effects of
chemotherapy and cytokine levels on patients’ quality of life and
fatigue.
The included studies were conducted on a variety of cancer
populations, including breast cancer[41,49,53,55], colorectal
cancer[45], head and neck cancer[51], lymphoma[50] and acute
myelogenous leukemia[22]. Hence, the type, dose intensity, route
of administration and duration of chemotherapy treatment varied
across the studies. The common chemotherapy drugs of interest
were doxorubicin, cyclophosphamide, methotrexate, irinotecan
and oxaliplatin. Examples of chemotherapy regimens that were
administered to patients included CAF/AC[55], CMF[55],
BEAC[50] and CHOP[50] (see Table 1).
The studies evaluated different cytokines, including pro-
inflammatory cytokines, anti-inflammatory cytokines and cytokine
receptors. The choice of cytokines for measurement was similar in
most studies. All of the selected studies measured the serum levels
of IL-1b, IL-6 or/and TNF-a. These cytokines were the
biomarkers of interest in these studies probably because they have
been shown to be strong candidates for mediating the components
of sickness behavior[11], including cognitive impairment in
neurological diseases such as Alzheimer’s disease and multiple
sclerosis[13,30]. Baseline assessments of cytokine levels and
cognitive functioning were performed in majority of the included
studies. However, subsequent measurements were conducted at
different time points, ranging from 24 hours to 3 years after
chemotherapy administration.
Subjective and/or objective cognitive assessments were carried
out to determine patients’ cognitive status. Objective assessments
involved traditional neuropsychological batteries such as Trail-
making test A and B[56], the Hopkins verbal learning test[57], and
computerized testing such as the CANTAB[58]. Subjective
assessments included self-report questionnaires using the
EORTC-QLQ-C30 health-related quality of life tool[59] and
the Functional Assessment of Cancer Therapy-Cognition (FACT-
Cog)[60]. Two of the studies used imaging techniques to evaluate
the relationship among structural changes in the brain, cognitive
impairment and cytokine dysregulation[41,53].
Summary of Selected Studies and Important Findings
Eight articles (six full manuscripts[22,41,50,51,53,55] and two
abstracts[45,49]) were included in this review (Table 1). Informa-
tion from full text and abstracts are presented separately.
One of the most recent studies was conducted by Ganz
et.al[53]. This prospective cohort study involved 49 chemother-
apy-receiving and 44 non-chemotherapy-receiving breast cancer
patients. Assessment on patients’ cognitive function was performed
using an objective neuropsychological (NP) battery and self-
reported Squire Memory Questionnaire, at baseline within 3
months of completing primary breast cancer treatment but before
initiating breast cancer targeted endocrine therapy, 6 months later
and 12 months later. Brain imaging with positron emission
tomography (PET) scans was evaluated in a subset of patients. The
authors observed an increase of sTNF-RII among chemotherapy
exposed patients, as compared to non-chemotherapy receiving
patients (25806100 pg/ml vs. 21136104 pg/ml; p= 0.0019).
Higher baseline sTNF-RII in chemotherapy patients was signif-
icantly associated with increased self-reported memory complaints.
In chemotherapy exposed patients, the longitudinal decline in
sTNF-RII was significantly correlated with fewer memory
complaints over 12 months (r =20.34, p = 0.04). No signification
association between objective neuropsychological tests and pro-
inflammatory cytokines was reported.
In another recently published cross-sectional study, Kesler
et.al[41] evaluated the association among serum cytokine levels,
left hippocampal volumes and objective memory performance in
20 chemotherapy-receiving breast cancer patients and 23 healthy
controls. The assessments were conducted 4.863.4 years post-
chemotherapy. It was found that the breast cancer group had
reduced left hippocampal volumes (p = 0.01) and cognitive
performance and evaluated levels of IL-6 (p = 0.003) and TNF-a
(p,0.0001), as compared to healthy controls. In the breast cancer
group, in the breast cancer group, lower left hippocampal volume
was associated with higher levels of TNF-a (b=21.56; p= 0.04)
and lower IL-6 (b=0.734, p = 0.03). The interaction between
TNF-a and IL-6 was also significant (b=1.23; p= 0.04). These
associations were not observed in the healthy control group.
Authors concluded post-chemotherapy altered hippocampal vol-
ume and verbal memory difficulties may be mediated by TNF-a
and IL-6 in breast cancer patients.
Cytokines and Cognitive Changes
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Janelsins et.al.[55] compared the severity of self-reported
cognitive disturbances and cytokine dysregulation (IL-6, IL-8,
and MCP-1) between 54 breast cancer patients who received
doxorubicin-based (with cyclophosphamide, or cyclophosphamide
plus fluorouracil; AC/CAF) chemotherapy or cyclophosphamide,
methotrexate, and fluorouracil (CMF), prior to on-study chemo-
therapy cycle 2 and after two consecutive chemotherapy cycles. It
was found that cytokine elevation of IL-6, IL-8, and MCP-1 was
more apparent in patients who received doxorubicin-based group
than the CMF group. Change in MCP-1 levels was negatively
associated with self-reported forgetfulness (p = 0.019).
The final selected study that involved breast cancer patients was
presented as an abstract[49]. Hence there is limited evidence and
conclusion drawn from this abstract. This case-control study
involved three groups of breast cancer patients: Cases who had
received chemotherapy and self-reported cognitive dysfunction on
Figure 2. Results of Literature Search.
doi:10.1371/journal.pone.0081234.g002
Cytokines and Cognitive Changes
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the FACT-Cog questionnaire. The 2 groups of controls involved
patients who received chemotherapy but did not report cognitive
problems, and another group that had breast cancer but did not
receive chemotherapy. Patients completed an objective NP, self-
reported FACT-Cog and functional MRI. In this preliminary
analysis, results showed that there was more pronounced self-
reported cognitive impairment in chemotherapy-receiving patients
than non-chemotherapy-receiving patients (p,0.0001). However,
objective cognitive testing revealed that more cognitive impair-
ment in non-chemotherapy-receiving patients than the other two
groups. Increased activity in the frontal areas was observed activity
in patients with greater objective cognitive impairment
(p,0.0005). However, there was no significant correlation
between symptoms and cytokine levels.
The other 4 studies were conducted in other cancer populations.
In the study conducted by Gan et.al[51], cognitive functioning of
five head and neck cancer patients who were treated with
radiotherapy and another 5 cancer patients who received both
with radiotherapy and cisplatin-based chemotherapy were evalu-
ated using objective NP tests and self-reported FACT-Cog. They
were assessed at baseline before their anti-cancer treatment and a
mean duration of 20 months later. It was found that patients
receiving cisplatin performed more poorly on objective CF than
patients who received only radiotherapy. However, the difference
was not statistically different and association was not established
between objective cognitive functioning and patients’ cytokine
levels.
A total of 54 myelogenous leukemia or myelodysplastic
syndrome were recruited in the Meyers et.al. study[22]. Objective
NP tests were administered at baseline before the start of their
chemotherapy treatment, and one month later. The patients’
cognitive performances and cytokines levels were compared
against population references and laboratory normative controls,
respectively. At baseline, patients’ cognitive functioning was below
reference values. Higher IL-6 levels also were associated with
worse performance on the executive functioning while higher IL-8
levels were related to better memory performance. However, it is
important to note that, there were insufficient individuals that had
follow-up cytokine levels and post-chemotherapy cognitive func-
tioning. Hence, limited conclusions can be drawn from this study.
Knobel et.al.[50] evaluated fatigue severity in a cross-sectional
study of 33 lymphoma patients 4–10 years after receiving the
chemotherapy regimen ABMT. Patients also completed the self-
reported cognitive functioning scale on the EORTC-QLQ-C30.
Their results were compared to general population norms. Results
showed that patients reported more cognitive disturbances than
the reference population (mean EORTC-QLQ-C30 cognitive
functioning score: 75 vs 89 points; p,0.001). Serum levels of IL-6,
sTNFR-p55, and sTNFR-p75 were slightly elevated in all clinical
groups of lymphoma patients compared to normal controls.
However, the association between cytokine levels and cognitive
disturbances was not assessed.
The last selected study is presented in an abstract[45]. This
prospective study was conducted on colorectal cancer patients.
The chemotherapy group consisted of 176 non-metastatic and 72
metastatic colorectal cancer patients, while the non-chemotherapy
group consisted of 117 colorectal cancer patients and 72 healthy
controls. Patients completed the self-reporting FACT-Cog, NP
tests and CANTAB, a computerized NP battery at baseline (pre-
chemotherapy), 6 months and 12 months later. Results showed
that cytokine levels were elevated in the chemotherapy group at all
3 time points of assessments (Data not shown; presented during
oral presentation at ICCTF Conference in 2012). However, thereT
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was no association between cytokine levels and cognitive
functioning.
Relationships among Chemotherapy, Cytokines and
Cognition
Although some studies observed dysregulation of cytokine levels
with chemotherapy[41,53,55], they reported conflicting evidence
with regards to the strength and direction of the association
between changes in cytokine levels and cognition. Ganz et.al.
concluded that higher levels of sTNF-RII correlated with lower
levels of baseline metabolism in the left inferior frontal gyrus in 17
breast cancer patients (r =20.55; p = 0.02)[53]. The same study
also found higher levels of sTNF-RII were significantly correlated
with greater memory complaints on the Squire Memory Ques-
tionnaire after controlling for age, body mass index, radiation and
depression, and time since last chemotherapy treatment among
the 43 patients who received chemotherapy (r =20.34,
p = 0.04)[53]. Kesler et.al. observed that lower left hippocampal
volume of the brain was associated with poorer verbal memory
performance, higher levels of TNF-a and lower levels of IL-6 in 20
chemotherapy-receiving breast cancer patients[41].
Meyers et.al. observed that pre-chemotherapy levels of circu-
lating IL-1, IL-6, IL-8 and TNF-a were higher in 54 chemother-
apy-receiving cancer patients than in laboratory normal con-
trols[22]. However, the same study did not assess the association
between post-chemotherapy cytokine levels and cognitive changes.
The other studies did not find a significant correlation between
cognitive impairment and cytokines[45,49–51]. Notably, the
conclusions drawn by some studies were limited by the small
sample size[50,51], or the lack of comparison with controls or
baseline/follow-up assessments[22,41,50].
As chemotherapy agents are usually administered in combina-
tions, it is more meaningful to evaluate the relationship between
cytokine-induced cognitive impairment and chemotherapy regi-
mens, rather than individual chemotherapeutic drugs. A recently
published review also suggested that the accumulation of a
combination of drugs, rather than individual drugs, may enhance
neurotoxicity in cancer patients[4]. One study examined the
effects of anthracycline-based (AC/CAF) chemotherapy and CMF
on cytokine levels and cognitive impairment[55]. Significant
increases in IL-6 (p = 0.042) and IL-8 (p = 0.060) levels were
observed in the AC/CAF treatment group, whereas IL-6 was
lowered in the CMF group (p = 0.054). Patients receiving AC/
CAF experienced more severe symptoms including heavy-head-
edness, difficulty thinking, and problems with concentration.
Similar degrees of forgetfulness were displayed in both groups of
patients. Knobel et.al. stated that poorer cognition was observed
among lymphoma patients who received a combination of
cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)
and methotrexate, compared with patients who received only
CHOP (data not presented) [50]. This study provided preliminary
evidence on how different chemotherapy regimens could affect
cytokine levels and cognitive functioning differently. It was
suggested that methotrexate’s ability to cross the BBB and obstruct
brain vascularization might have caused the cognitive impair-
ment[61–63].
The time concordance between the onset of cytokine induction
and the occurrence of cognitive impairment was not clearly
elucidated in these studies. Notably, the current evidence could
not ascertain the exact timing of the onset of cognitive
impairment[64–67]. One study reported that the circulating level
of sTNF-RII was elevated at 6 months post-chemotherapy and
declined to a level similar to that of non-chemotherapy controls at
12 months post-chemotherapy and an increase in cognitive
complaints from baseline was significantly correlated with
increases in sTNF-RII levels (p = 0.05)[53]. Evidence on the onset
and duration of cytokine induction thus remains inconclusive.
Confounding Factors
Through this review, we identified a number of confounders
that contributed to the heterogeneity of the studies which were not
sufficiently accounted for. These confounders need to be evaluated
and accounted for when studying the relationship between
chemotherapy-associated cytokine induction and cognitive im-
pairment. This discussion also forms the basis of our recommen-
dations for future research.
1. Effects of cancer. The study populations differed among the
selected studies; they included patients with different types and
stages of cancers. Studies have shown that cancer cells are
capable of producing cytokines [18,29]. For example, it was
found that TNF and transforming growth factor (TGF) were
elevated in patients with early-stage cancers, whereas patients
with progressive disease had elevated levels of angiogenin,
granulocyte macrophage colony-stimulating factor and TNF-b
[18]. Hence, it is difficult to determine whether an elevated
cytokine level is partially or entirely caused by chemotherapy,
the progression of cancer or a combination of both. Non-
cancer controls may not fully eliminate the effects of cancer on
cytokine levels as studies have shown that there may be a
potential dysregulation of cytokine levels in subclinical cancer
states observed in healthy subjects[68,69]. Notably, individual
variability (such as disease progression) can still exist within
cancer controls. It is plausible that cytokine induction
attributed by the different nature of cancers and anti-cancer
treatments may cause varying levels of cognitive impairment in
patients.
2. Effects of gender. Two studies evaluated the effects of
gender on cognitive changes[46,50]. Males demonstrated more
cognitive impairment than females on objective cognitive tests,
although subjective (self-reported) cognitive complaints were
higher among females[46,50]. It is postulated that higher levels
of estrogen can offer neuro-protection, antioxidant proper-
ties[70] and maintenance of telomere lengths to protect against
atrophic changes in the brain[71]. Although serum sex
hormone levels have been measured[45], analysis was not
performed to investigate their correlation with serum cytokine
levels. The decrease in estrogen after menopause may increase
pro-inflammatory IL-6 and TNF-a cytokine activity[24].
Higher subjective cognitive impairment among females may
be attributable to neuroendocrine-related problems arising
from chemotherapy-induced or aging-related meno-
pause[72,73]. Studies have also revealed that testosterone
replacement, which can potentially shift the cytokine balance to
a state of reduced inflammation and suppress the expression of
the pro-inflammatory cytokines TNF-a, IL-1b and IL-6, has
been shown to improve some aspects of cognitive ability in
males[74–76]. Therefore, the receipt of anti-hormonal treat-
ment must be taken in account in the assessment of cognitive
changes in patients, especially in cancers such as prostate,
testicular and breast cancers.
3. Effects of aging. The age of subjects across the selected
studies ranged widely, from 18 to 84 years. With the exception
of one study[53], age was not routinely adjusted as a
confounding factor. It was proposed that cancer treatments
can cause cognitive impairment through the acceleration of the
aging process, and the biologic mechanisms underlying cancer,
cancer treatments, aging, neurodegeneration, and cognitive
Cytokines and Cognitive Changes
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decline are interconnected[77]. Aging may be associated with
increase in IL-6, TNF-a and TNFR, regardless of comorbid-
ities[30,78–80]. Age-related impairment is also associated with
increased hypothalamic IL-1b, which can damage the neuronal
membrane through lipid peroxidation, leading to memory and
learning deficits[12,30]. Therefore, age is an important
determinant in the measurement of cytokine levels and
cognitive impairment[3,81].
4. Effects of genetic predisposition. Most of the selected
studies did not account for genetic predisposition. Only two
studies performed genotyping for the apoE gene[45,49], one of
which reported that cognitive changes were not associated with
the apoE genotype or elevated cytokine levels[45]. Yet, the
apoE genotype has been associated with increased susceptibility
to damage in the central nervous system and cognitive
impairment[15]. Excessive secretion of pro-inflammatory
cytokines such as IL-6 and IL-1 can occur in genetically
predisposed individuals under stress[30,82]. Genetic polymor-
phisms may influence cytokine activity in Alzheimer’s disease
and depression. It is worthwhile noting that other than the
apoE genotype, polymorphisms in other cytokine gene variants
may result in disrupted levels of cytokines[21,26,83] and may
potentially affect cognition. One study discovered that a single-
nucleotide polymorphism in the TNF-a-308 gene is associated
with more severe cognitive deficits on three independent
measures, namely, PAOFI Memory (p=0.03), the Squire
subjective memory questionnaire (p=0.04) and the Multidi-
mensional Fatigue Symptom Inventory – Mental
(p=0.005)[54]. Future study can focus on the identification
of candidate genes that can influence cytokine activity and are
associated with chemotherapy-induced neurotoxicity in cancer
patients.
5. Effects of disturbances in the sleep-wake cycle.
Increased serum cytokine levels have been found among
cancer patients with dampened circadian rhythms[27]. Disor-
dered sleep induces an inflammatory response that leads to an
increase in IL-6 and TGF-a. These cytokines, termed
nocturnal cytokines, have been shown to affect the sleep-wake
cycle, causing a disruption in the neuroendocrine control of
cortisol release, resulting in further release of pro-inflammatory
cytokines[23]. Moreover, dysregulation in sleep is linked to
cognitive impairment in the domains of attention, executive
function and motor control ability[30,84–86].
6. Effects of psychosocial characteristics (fatigue, de-
pression, anxiety and stress). Fatigue, depression, anxi-
ety, distress and mood changes have been found to reduce
patients’ cognitive functioning and could be mediated by
chemotherapy-induced cytokines. A meta-analysis revealed a
correlation between fatigue and serum cytokine levels of IL-6
and IL-1RA[87]. However, none of the three selected
studies[45,49,50] that measured fatigue as one of their
endpoints showed a correlation between cytokine levels and
the occurrence of fatigue. Depression is found to disrupt the
hypothalamic-pituitary-adrenal axis and production of cortisol
and pro-inflammatory cytokines[13,29,30,88,89] through a
positive feedback mechanism. To reinforce this relationship,
studies have shown the effects of antidepressants on the
reduction of pro-inflammatory cytokine levels[19]. Note that
patients’ reports of cognitive problems during chemotherapy
treatment were typically not related to objective cognitive test
results, but to psychosocial parameters such as anxiety and
depression[90].
Directions for Future Research
Based on the evidence and limitations of this review, a list of
recommendations is proposed to improve the investigation of
chemotherapy-induced cytokines as a biological determinant of
cognitive changes in cancer patients (Table 2). To summarize, in
line with ICCTF’s recommendations, it is suggested that studies of
this subject matter should include a longitudinal design, appro-
priate choices of chemotherapy-receiving cancer patients, disease
specific and healthy controls, inclusion of baseline and post-
chemotherapy standard neuropsychological assessments and
robust statistical analysis of longitudinal data[91]. In addition to
these recommendations, it is also important to standardize the
protocol and timing for the blood draw and measurement of
cytokine levels, and account for the confounding factors
mentioned in Figure 1. In particular, studies should control for
anxiety, depressive and fatigue symptoms that are known widely in
literature to be associated with cancer- and chemotherapy-induced
cytokine activity[29].
To evaluate the role of cytokines as mediator between
chemotherapy and cognitive impairment, it is recommended that
investigators could provide a rationale behind the choice of
cytokines or biomarkers tested in the studies. Other than the
known pro-inflammatory cytokines (such as IL-1b, TNF-a and IL-
6) that are associated with cognitive impairment, it may be
worthwhile to evaluate the relationship between neurotoxicity and
other less explored biomarkers, such as anti-inflammatory
cytokines and vascular endothelial growth factor (VEGF) which
may potentially exert a neuro-protective effect. For example, it has
been suggested that VEGF can stimulate angiogenesis and
modulate vascular permeability and promote neurogenesis[92].
Novel technologies such as multiplex immunoassay can be applied
to enable the analysis of several cytokines of interest simulta-
neously[45,93]. Commercially available bead-conjugated antibod-
ies permit the measurement of up to 25 different cytokines within a
sample[93]. Validation studies have shown that results of multiplex
immunoassay well correlate with traditional enzyme linked
immunosorbent assay (ELISA) for a large majority of human
cytokines and biomarkers[94,95]. Multiplex immunoassay also
requires lower-volume samples to detect cytokines over a broad
dynamic range of concentrations in a more cost-effective
way[93,96–98]. This advantage is favorable for longitudinal
studies that have high attrition rates, as there may be a limited
number of samples to conduct ELISA[93]. If resources allow, key
genotypes that affect cytokine-induced cognitive impairment
should be explored to investigate the role of genetic determinants
in the induction of cytokines.
The multi-factorial characteristic of this type of study also calls
for a more robust analysis of the statistical data and an account of
the various etiological agents involved. The use of Principal
Component Analysis (PCA)[99] is suggested to facilitate the
reorganization of data and examine the causes of variance in the
data. For example, one group successfully used this technique to
identify the association between baseline cancer-related fatigue
and IL-6, IL-6R and IL-17 (variance = 78%)[100].
Other than clinical studies, animal models also offer several
advantages for evaluating the effect of chemotherapy on cognitive
outcomes[101–104]. Animal models can eliminate numerous
confounders outlined in this review, such as the cancer itself,
psychosocial characteristics and presence of other comorbidities.
The time of administration of chemotherapeutic drugs, behavioral
assessments and blood draw can be standardized in animal studies
to reduce the variability observed in clinical studies. Results from
animal models can aid in elucidating the biological mechanisms
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involved in chemotherapy-induced cognitive changes and the
specific underlying brain regions involved.
All current studies of this subject matter attempt to measure
cytokine concentration in patients’ serum/plasma, and not the
cerebrospinal fluid (CSF). However, it is logistically challenging to
obtain CSF from subjects in a research setting. It is proposed that
for future studies that involve intrathecal administration of
chemotherapeutic drugs, especially in leukemia patients, CSF
can be collected to examine the relationship between the
concentration of cytokine in CSF and cognitive functioning before
and after the cancer treatment.
Results from recent published imaging studies also support the
hypothesis that chemotherapy affects the brain structure and
provide research directions for candidate mechanisms of chemo-
therapy-associated cognitive change. Two included studies exam-
ined the relationship among structural changes in the brain,
cytokine levels and cognitive impairment[41,53]. One of the
studies found that IL-6 and TNF-a levels and hippocampal
volumes were associated with verbal memory functioning despite
its relatively small sample size[41]. Imaging studies play an
important role in complementing and providing support for the
role of pro-inflammatory cytokines in chemotherapy-associated
brain injury and subsequent cognitive impairment. It allows
researchers to identify the specific site of cognitive impairment and
their relationship with physiological biomarkers.
Finally, research gaps remain to be filled regarding the role of
cytokines in relation to cognitive changes in cancer patients
(Table 3). Other than understanding the pattern of changes in
cytokine levels during cancer treatment, it is also important to
elucidate the effect size of the change that constitutes a significant
clinical difference in cognitive functioning. Striving towards the
answers to these research questions will lead to a better
understanding of this neurocognitive phenomenon in cancer
patients. It would be worthwhile to reflect upon what we know
currently about this subject matter, and determine whether these
terms are appropriate in describing this phenomenon. The terms
‘‘chemobrain’’ or ‘‘chemofog’’ may not accurately reflect the
complexity of the multiple potential etiologies contributing to this
Table 2. Recommended methodological guidelines for future studies.
Criteria Description Checklist
Experimental methods
Inclusion of suitable controls
(non-chemotherapy cancer
patients with similar demographics).
To account for cytokine levels and cognitive
impairment in cancer patients without chemotherapy.
Did the study include controls who do not require
chemotherapy, and who had the identical type of
cancer and demographics as the sample population?
Account for co-morbidities To account for changes in cytokine levels and
cognitive impairment as a result of chemotherapy,
rather than other factors.
Did the study account for non-cancer disease states?
(anemia, depression, anxiety,
Alzheimer’s disease, multiple
sclerosis, Parkinson’s, dementia,
traumatic brain injury, etc.).
Account for other forms of
treatment than chemotherapy.
To account for changes in cytokine levels and
cognitive impairment as a result of chemotherapy,
rather than other forms of treatment.
Did the study account for patients who were receiving
other forms of therapy that may affect cytokine levels
and cognitive impairment?
(hormonal therapy, cytokine therapy,
radiation, antidepressants, etc.).
Chemotherapy information
Inclusion of specific chemotherapeutic
agents or regimens for assessment.
To understand the pharmacological effects of
cytokine-induced cognitive impairment.
Did the study provide clear data regarding the type of
chemotherapeutic drugs/regimen involved, the
duration, cycles, doses, dose intensity and route of
administration of the chemotherapy treatment?
Inclusion of specific dose intensity,
route of administration and duration of
chemotherapeutic treatment.
To understand whether there is a correlation
between route of administration/strength and
duration of dosing with cytokine levels and
cognitive impairment.
Cytokine measurement
Inclusion of both pre-chemotherapy
baseline and post-chemotherapy
assessments at appropriate intervals.
To account for changes in cytokine levels as
a result of chemotherapy by comparing baseline
measurement with post-chemotherapy measurement.
Were measurements carried out before and after
patients received chemotherapy/surgery?
If applicable, inclusion of pre-surgical
baseline and post-surgical assessments
at appropriate intervals.
To account for changes in cytokine levels as a
result of tumor progression/tumor load by
comparing pre-surgical measurement with
post-surgical measurement.
Inclusion of specific cytokines involved
in the study.
To identify the specific cytokine and its
effects on cognitive impairment.
Did the study specify the types of cytokines to be
tested for?
Accounting for accuracy of testing. To minimize discrepancies in results due
to the handling and processing of samples.
Did the study utilize published procedures for the
testing of cytokine levels?
Inclusion of standardized timing across the
samples for extraction of blood samples.
Different timings of extraction may result in
different levels of cytokines.
Did the study indicate a specific time for the extraction
of cytokines from the sample and control population?
doi:10.1371/journal.pone.0081234.t002
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problem[105]. Results of this review suggest that cognitive
impairment may represent a component of the cytokines- and
inflammatory markers- mediated cluster of cancer- and treatment-
related symptoms, such as fatigue, depression and stress.
Limitations of this review
Despite the well-defined inclusion criteria, the reviewed articles
were heterogeneous in nature and a quality appraisal strategy
could not be applied to them. Knowledge on the subject matter is
in its infancy, and the availability of literature to substantiate and
justify the findings from the selected studies is sparse. Moreover,
conclusions drawn from the two abstracts are tentative in nature
and subjected to changes when they are published.
Conclusion
Although some of the selected studies observed that patients on
chemotherapy experienced cognitive impairment and dysregula-
tion in pro-inflammatory cytokines of IL-1b, IL-6 and TNF-a,
there is limited evidence to suggest that there is an association
between the severity of cognitive impairment and cytokine
dysregulation. Our results suggest that the intermediary role of
cytokines in post-chemotherapy cognitive impairment is still
controversial and requires further evaluation. Notably, due to
the high heterogeneity of the studies included in this review, it is
difficult to draw conclusive inferences regarding the causal
relationship between chemotherapy and cytokine-induced cogni-
tive impairment.
Understanding the mechanisms of the cytokines as mediators in
chemotherapy-induced cognitive impairment will improve our
knowledge of the clinical implications of ‘chemobrain.’ It is
anticipated that the harmonization of methodologies will allow the
pooling of results from robust studies and thus provide further
insights on this subject matter. Such information will enable
scientists with pharmacological insights to formulate therapies or
appropriately adjust the current treatment regimes to minimize the
effects of cytokine-induced cognitive impairment in patients with
cancer.
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